In Brief: Bayer Cipro
Executive Summary
Bayer Cipro: Ciprofloxacin approved June 5 for treatment of mild to moderate acute sinusitis caused by S. pneumoniae, H. influenzae and M. catarrhalis at a recommended adult dosage of 500 mg b.i.d. for 10 days. A trial comparing Cipro to cefuroxime for acute sinusitis demonstrated 77% resolution for Cipro and 71% for cefuroxime after 30 days of follow-up, Bayer says. Another comparative trial showed 96% resolution for Cipro and 90% for clarithromycin at 30 days...